ATE480256T1 - Plazentäre alkalische phosphatase zur diabeteskontrolle - Google Patents

Plazentäre alkalische phosphatase zur diabeteskontrolle

Info

Publication number: ATE480256T1
Authority: AT; Austria
Prior art keywords: alkaline phosphatase; treatment regimens; human; methods; diabetes
Prior art date: 2002-12-12

Application number

AT03796758T

Other languages

English (en)

Inventor

Zoltan Kiss

Original Assignee

Zoltan Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-12

Filing date

2003-12-05

Publication date

2010-09-15

2003-12-05 Application filed by Zoltan Lab filed Critical Zoltan Lab

2003-12-05 Priority claimed from PCT/US2003/038838 external-priority patent/WO2004054609A1/en

2010-09-15 Application granted granted Critical

2010-09-15 Publication of ATE480256T1 publication Critical patent/ATE480256T1/de

Links

206010012601 diabetes mellitus Diseases 0.000 title abstract 2
102000002260 Alkaline Phosphatase Human genes 0.000 title 1
108020004774 Alkaline Phosphatase Proteins 0.000 title 1
238000000034 method Methods 0.000 abstract 4
238000011269 treatment regimen Methods 0.000 abstract 3
102100024321 Alkaline phosphatase, placental type Human genes 0.000 abstract 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
239000008280 blood Substances 0.000 abstract 2
210000004369 blood Anatomy 0.000 abstract 2
239000008103 glucose Substances 0.000 abstract 2
108010031345 placental alkaline phosphatase Proteins 0.000 abstract 2
241000282412 Homo Species 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
230000003178 anti-diabetic effect Effects 0.000 abstract 1
239000003472 antidiabetic agent Substances 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
230000004584 weight gain Effects 0.000 abstract 1
235000019786 weight gain Nutrition 0.000 abstract 1
230000004580 weight loss Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03001—Alkaline phosphatase (3.1.3.1)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Zoology (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
General Chemical & Material Sciences (AREA)
General Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Hematology (AREA)
Obesity (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Dispersion Chemistry (AREA)
Biotechnology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT03796758T 2002-12-12 2003-12-05 Plazentäre alkalische phosphatase zur diabeteskontrolle ATE480256T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US10/317,916 US7048914B2 (en)	2002-12-12	2002-12-12	Placental alkaline phosphatase to control diabetes
US10/441,992 US7014852B2 (en)	2002-12-12	2003-05-20	Alkaline phosphatase to induce weight loss or to reduce weight gain
PCT/US2003/038838 WO2004054609A1 (en)	2002-12-12	2003-12-05	Placental alkaline phosphatase to control diabetes

Publications (1)

Publication Number	Publication Date
ATE480256T1 true ATE480256T1 (de)	2010-09-15

Family

ID=32506246

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03796758T ATE480256T1 (de)	2002-12-12	2003-12-05	Plazentäre alkalische phosphatase zur diabeteskontrolle

Country Status (6)

Country	Link
US (4)	US7048914B2 (de)
EP (1)	EP1733734B1 (de)
AT (1)	ATE480256T1 (de)
DE (1)	DE60334147D1 (de)
DK (1)	DK1572230T3 (de)
ES (1)	ES2354976T3 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7048914B2 (en) *	2002-12-12	2006-05-23	Zoltan Laboratories	Placental alkaline phosphatase to control diabetes
EP1572230B1 (de) *	2002-12-12	2010-09-08	Zoltan Laboratories	Plazentäre alkalische phosphatase zur diabeteskontrolle
US20080279843A1 (en) *	2003-12-09	2008-11-13	Essential Skincare, Llc	Method For Improving Insulin Sensitivity By Administering an Inhibitor of Antitrypsin
CN1917899B (zh)	2004-02-04	2013-04-17	塞浦西斯阿瓦药物集团	碱性磷酸酶对存在于粘膜屏障的脂多糖解毒的用途
US20110142817A1 (en) *	2004-02-04	2011-06-16	Pharmaaware Sepsis B.V.	Means and method for treating and/or preventing necrotizing enterocolitis
EP1753446A4 (de) *	2004-05-27	2009-10-28	Essential Skincare Llc	Alpha-1-säure-glykoprotein zur behandlung von diabetes
WO2007081654A2 (en) *	2005-12-28	2007-07-19	Zoltan Laboratories Llc	Compositions and methods to enhance viability and function of islet cells
WO2007076505A2 (en) *	2005-12-28	2007-07-05	Essential Skincare, Llc	Transferrin and transferrin-based compositions for diabetes treatment
EP1965830B1 (de) *	2005-12-28	2014-05-14	Zoltan Laboratories Llc	Verwendung von alkalischer phosphatase zur erhaltung von gesunder gewebemasse bei säugetieren
EP1952823A1 (de) *	2007-01-30	2008-08-06	AM-Pharma B.V.	Verwendung von alkalischer Phosphatase bei der Behandlung eingeschränkter Nierenfunktion
US20090317372A1 (en) *	2008-06-20	2009-12-24	Zoltan Kiss	Small molecules for the reduction of high blood glucose level
US20100093603A1 (en) *	2008-07-17	2010-04-15	Kenneth Baker	Use of organic compounds
US20100215635A1 (en) *	2009-02-23	2010-08-26	Zoltan Kiss	Small molecules to induce weight loss or to reduce weight gain
US20130251701A1 (en) *	2010-10-22	2013-09-26	Zoltan Kiss Consulting	Alkaline phosphatase to correct insulin resistance, hyperinsulinemia, and dyslipidemia
WO2012177497A1 (en) *	2011-06-20	2012-12-27	Wisconsin Alumni Research Foundation	Method to inhibit neuropathic pain by intrathecal injection of protein phosphatases
PE20161442A1 (es)	2014-01-24	2017-01-12	Am-Pharma B V	Proteinas quimericas tipo fosfatasa alcalina
PT3461891T (pt)	2014-01-24	2020-07-30	Am Pharma Bv	Processamento a jusante de uma fosfatase alcalina
US10709773B2 (en)	2015-03-06	2020-07-14	Synthetic Biologics, Inc.	Safe and effective beta-lactamase dosing for microbiome protection
CA3057089A1 (en)	2017-03-21	2018-09-27	Synthetic Biologics, Inc.	Alkaline phosphatase formulations
EP3737750B1 (de)	2018-01-09	2024-06-05	Theriva Biologics, Inc.	Alkalische phosphatasemittel zur behandlung von entwicklungsstörungen des nervensystems
ES3032290T3 (en)	2018-03-20	2025-07-16	Theriva Biologics Inc	Intestinal alkaline phosphatase formulations
WO2019183209A1 (en)	2018-03-20	2019-09-26	Synthetic Biologics, Inc.	Alkaline phosphatase agents for treatment of radiation disorders
AU2020270046B2 (en)	2019-05-06	2026-02-05	Theriva Biologics, Inc.	Alkaline phosphate-based oncology treatments
AU2020287084B2 (en)	2019-06-03	2025-12-18	Theriva Biologics, Inc.	Alkaline phosphatase formulations and uses thereof
CA3146738A1 (en)	2019-07-18	2021-01-21	Synthetic Biologics, Inc.	Intestinal alkaline phosphatase-based treatments of metabolic disorders
US20240307509A1 (en) *	2021-01-06	2024-09-19	Mnpharm Sbc	Placental alkaline phosphatase for starting early treatment of cancer patients exhibiting no detectable loss of body and muscle weight as yet to prevent or reduce the loss of muscle proteins
WO2022177547A1 (en) *	2021-02-16	2022-08-25	Zoltan Laboratories, Llc	Placental alkaline phosphatase for reducing the loss of red blood cells, white blood cells, and platelets in chemotherapy treated cancer patients

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4030995A (en) *	1976-07-13	1977-06-21	Sigma Chemical Company	Alkaline phosphatase isoenzyme determination
GB1594389A (en)	1977-06-03	1981-07-30	Max Planck Gesellschaft	Dressing material for wounds
IT1108964B (it) *	1978-01-20	1985-12-16	Sclavo Inst Sieroterapeut	Composizione adatta all'analisi della fosfatasi alcalina e metodo utilizzante la stessa
US4265233A (en)	1978-04-12	1981-05-05	Unitika Ltd.	Material for wound healing
DE3007226A1 (de)	1980-02-27	1981-09-10	Erich 2400 Lübeck Hofacker	Arzneikapsel
SU1138410A1 (ru)	1982-09-10	1985-02-07	Астраханский государственный медицинский институт им.А.В.Луначарского	Способ выделени термостабильной плацентарной щелочной фосфатазы
US4818540A (en)	1985-02-25	1989-04-04	Rutgers, The State University Of New Jersey	Transdermal fertility control system and process
JPS61277626A (ja)	1985-05-31	1986-12-08	Sugiura Shinyaku Kaihatsu Kenkyusho:Kk	ス−パ−オキシドジスムタ−ゼを高濃度に含有する胎盤エキスおよびその製法
DE3836971C1 (de)	1988-10-31	1990-05-17	Weck, Wolfgang, Dr.Med., 6990 Bad Mergentheim, De
JPH05506673A (ja)	1991-02-22	1993-09-30	アムジエン・インコーポレーテツド	迅速な創傷の治癒を促進するためのｇｍ―ｃｓｆ及びｇ―ｃｓｆの使用
AU678764B2 (en)	1992-06-03	1997-06-12	Case Western Reserve University	Bandage for continuous application of biologicals
WO1995005455A1 (en) *	1993-08-13	1995-02-23	Rijksuniversiteit Te Groningen	Pharmaceutical composition comprising phosphatase or a derivative thereof
US5707624A (en)	1994-06-03	1998-01-13	The Regents Of The University Of Michigan	Treatment of Kaposi's sarcoma by inhibition of scatter factor
US5932779A (en)	1996-06-10	1999-08-03	Millennium Pharmaceuticals, Inc.	Screening methods for compounds useful in the regulation of body weight
US6005000A (en)	1996-08-22	1999-12-21	Oxis International, Inc.	5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor
US6414036B1 (en)	1999-09-01	2002-07-02	Van Beek Global/Ninkov Llc	Composition for treatment of infections of humans and animals
US6627425B1 (en) *	2000-06-02	2003-09-30	Millennium Pharmaceuticals, Inc.	Human glucose-6-phosphatase molecules and uses thereof
US7011965B2 (en)	2001-03-09	2006-03-14	Regents Of The University Of Minnesota	Compositions and methods for stimulating wound healing and fibroblast proliferation
US7048914B2 (en)	2002-12-12	2006-05-23	Zoltan Laboratories	Placental alkaline phosphatase to control diabetes
EP1572230B1 (de)	2002-12-12	2010-09-08	Zoltan Laboratories	Plazentäre alkalische phosphatase zur diabeteskontrolle
US7374754B2 (en)	2003-09-02	2008-05-20	Essential Skincare, Llc	Use of placental alkaline phosphatase to promote skin cell proliferation
EP1965830B1 (de)	2005-12-28	2014-05-14	Zoltan Laboratories Llc	Verwendung von alkalischer phosphatase zur erhaltung von gesunder gewebemasse bei säugetieren

2002
- 2002-12-12 US US10/317,916 patent/US7048914B2/en not_active Expired - Lifetime
2003
- 2003-05-20 US US10/441,992 patent/US7014852B2/en not_active Expired - Lifetime
- 2003-12-05 DK DK03796758.5T patent/DK1572230T3/da active
- 2003-12-05 EP EP06018710.1A patent/EP1733734B1/de not_active Expired - Lifetime
- 2003-12-05 AT AT03796758T patent/ATE480256T1/de active
- 2003-12-05 DE DE60334147T patent/DE60334147D1/de not_active Expired - Lifetime
- 2003-12-05 ES ES03796758T patent/ES2354976T3/es not_active Expired - Lifetime
2009
- 2009-01-28 US US12/361,310 patent/US7858085B2/en not_active Expired - Fee Related
2010
- 2010-11-17 US US12/948,146 patent/US8603464B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1733734B1 (de)	2020-01-22
ES2354976T3 (es)	2011-03-21
US7048914B2 (en)	2006-05-23
DK1572230T3 (da)	2011-01-03
US7014852B2 (en)	2006-03-21
US20040115185A1 (en)	2004-06-17
US20040120940A1 (en)	2004-06-24
EP1733734A3 (de)	2011-09-28
US20110123513A1 (en)	2011-05-26
DE60334147D1 (de)	2010-10-21
US20090130080A1 (en)	2009-05-21
EP1733734A2 (de)	2006-12-20
US7858085B2 (en)	2010-12-28
US8603464B2 (en)	2013-12-10

Legal Events

Date

Code

Title

Description

2011-05-15

UEP

Publication of translation of european patent specification

Ref document number: 1572230

Country of ref document: EP

Publication	Publication Date	Title
DE60334147D1 (de)	2010-10-21	Plazentäre alkalische phosphatase zur diabeteskontrolle
LU91544I2 (fr)	2009-05-25	Alpha alglucosidase
EA200000747A1 (ru)	2000-12-25	СПОСОБ ВВЕДЕНИЯ AspB28-ИНСУЛИНА ЧЕЛОВЕКА
NO20020211L (no)	1997-08-19	Anvendelse av deskarboksyloratadin for fremstilling av et farmasöytisk preparat for behandling av medisinske tilstander
DK1316308T3 (da)	2007-03-05	Transdermalt terapeutisk plaster med capsaicin og capsaicin-analoger
MXPA03006217A (es)	2004-10-15	Sistema de administracion espaciada de farmacos.
WO2000016797A3 (en)	2000-05-25	Use of glp-1 or analogs in treatment of stroke
DE60115432D1 (de)	2006-01-05	Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
DE60018409D1 (de)	2005-04-07	Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren
ATE161725T1 (de)	1998-01-15	Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
SE9003887L (sv)	1992-06-07	Cellproliferationsmatris och anvaendning daerav
WO1998030223B1 (en)	1998-10-01	Cytokine related treatments of disease
GR3032224T3 (en)	2000-04-27	Therapeutic agent for threatened abortion.
KR900007434A (ko)	1990-06-01	시스타틴을 유효 성분으로하는 치료제
Beitner et al.	1980	Prostaglandin E1 treatment of leg ulcers caused by venous or arterial incompetence
RU2005102923A (ru)	2005-10-10	Средство от диабета
WO2005087255A3 (en)	2006-04-20	Method of optimizing treatment with interferon-tau
DE602004025040D1 (de)	2010-02-25	Den blutzuckerspiegel bei diabetes mellitus regulierendes tetrapeptid
PT1156791E (pt)	2005-08-31	Bupropiona para tratar doencas virais
KR890001555A (ko)	1989-03-27	요산 배설용 조성물
IL110888A0 (en)	1994-11-28	Pharmaceutical compositions for the treatment of liver diseases comprising a benzothiazepine derivative
RU2000108989A (ru)	2002-05-20	Способ профилактики и лечения респираторных болезней телят
DE60120371D1 (de)	2006-07-20	Verwendung von wachstumshormon in niederen dosen
UA23921A (uk)	1998-08-31	Спосіб лікування шлунково-стравохідного рефлюксу
RU2001120483A (ru)	2003-08-10	Способ лечения больных нейросенсорной тугоухостью в остром периоде